skip to main content, skip to Quick links, or skip to Search

main content

Current Seizure Studies and Events at NCSU-CVM

Boy with dog

(Recruiting for cases)

NEW: Canine Epilepsy Symposium 2014

North Carolina State University's College of Veterinary Medicine is hosting a symposium on Understanding Canine Epilepsy on Saturday, March 22nd, from 9-11am (lunch included). For full details, view the symposium announcement. Register online or contact Julie Nettifee-Osborne to ensure your spot!

2014 Ongoing Canine Epilepsy Clinical Trial:

North Carolina State University's College of Veterinary Medicine is participating in a national clinical trial evaluating a new drug to treat canine idiopathic epilepsy. Qualifying canine patients must be at least four months old, not previously treated with anti-seizure medicaiton, weigh at least 1.5 kg, have no previous history of seizure clusters, and not be pregnant. Candidates must be seen by the clinical investigator within seven days of the most recent seizure. Dogs that meet the initial eligibility criteria receive free medical evaluations and diagnostic tests. Dogs that are enrolled in the treatment phase of the study receive free medication (no placebo) and monthly exams as well as an MRI if patient qualifies for study. For more information regarding this project, please contact study coordinator Julie Osborne, julie_osborne@ncsu.edu 919-513-6812.

Impacts of Epilepsy in Companion Animal Patients (Fall 2012 Study Closed)

With epilepsy affecting more than 5% of the canine population, the impacts of owning a pet with epilepsy can be significant. As a part of our ongoing research related to epilepsy in companion animals, we hope to gather information from an online study Impacts of Epilepsy in Companion Animal Patients, designed to explore impacts such as costs, benefits, relationships with other companions in the household and more to better support owners and their pets.

This research will also support our efforts to obtain future funding for additional clinical research by increasing our knowledge related to many factors centered on living with a pet with epilepsy and long-term support opportunities for the veterinary profession.

The survey author, Julie Nettifee Osborne, RVT, BS, VTS (Neurology organizing committee) under the direction of Dr. Karen Munana, will also provide valuable ideas for future companion animal outreach, education and research.

Canine Keppra Pharmacokinetic Study III: Study Closed 2012

Recruitment is open for dogs with epilepsy that are being treated with Keppra (levetiracetam) and Phenobarbital (group I) Keppra and Potassium Bromide (group II) , or Keppra, Phenobarbital and Potassium Bromide (group III) for a Pharmacokinetic study. This study is being conducted at North Carolina State Unversity-College of Veterinary Medicine, under the direction of Dr. Karen Munana, DVM, DACVIM (Neurology).

If your dog has been diagnosed with epilepsy, and is receiving the drugs listed above in any of the 3 groups listed, we are interested in sampling your pet to determine how Keppra interacts with the other anticonvulsants through sequential blood sampling in a one-day study. All blood levels will be provided to the owners at no-charge. If you are interested in more information regarding this project, or to see if your pet qualifies, please contact Julie Osborne, julie_osborne@ncsu.edu or 919-513-6812. We would like to thank Toby's Foundation, www.tobysfoundation.org for their assistance in the funding of this important project.

 

Does the MDR-1 Gene Influence Treatment Response in Canine Epilepsy?

Building Links to Greater Knowledge, Treatments

 

Recruitment of this study is closed, as of summer 2010: Investigations underway at North Carolina State University-College of Veterinary Medicine are examining how genetics may play a role in why some dogs respond poorly to seizure medication. Dr. Karen Munana, associate professor of neurology is collaborating with a Dr. Katrina Mealey at Washington State University in the first investigation, which evaluates the effect of a specific known genetic deletion seen in Collies on seizure control. This deletion makes these dogs more susceptible to side effects of certain drugs, and the study aims to determine whether it also affects the response to seizure medication. The study is seeking Collies with seizures that are being treated with seizure medication to participate. For more information regarding the results of this project please contact study coordinator Julie_Osborne@ncsu.edu or 919-513-6812.